D irect in vivo transfer of genetic material into the arterial wall offers an experimental approach to (1) the study of the role of individual genes in vascular pathophysiology and (2) the development of localized gene therapies for vascular disorders.1,2 Optimal features for a system of in vivo arterial gene transfer would include high efficiency (as measured by the percentage of target cells into which gene transfer occurred), significant levels of gene expression (as measured by the mass of recombinant gene product present in arterial tissue extracts), and an ability to identify specifically in tissue sections the cells into which gene transfer had occurred. A model gene transfer system that includes all of these features would facilitate the performance of both pathophysiological and therapeutic experiments. Several groups have reported data generated in animal models of in vivo arterial gene transfer, using either viral or plasmid vectors.3-9 None of these model systems, however, incorporate all of the three features listed above: high efficiency, significant mass of recombinant protein, and specific cellular localization.
Low efficiency has been a recurrent problem in arterial gene transfer studies. In a previous study, we estimated the efficiency of retroviral vector-mediated arterial gene transfer at fewer than 100 cells per vessel. 5 Leclerc et al0 reported gene transfer into fewer than 1 in 103 cells, using a liposome-assisted technique of plasmid transfection. No definitive study has yet presented quantitative data that support an in vivo arterial gene transfer efficiency higher than that reported in these two studies.
Three groups have reported calculations of the mass of recombinant protein produced after arterial gene transfer. 4,7,8"11 These calculations have all been based on measurements of luciferase activity, with conversion to luciferase mass by reference to a luciferase preparation of known specific activity. Reported levels of recombinant luciferase have been low, in the range of femtograms to picograms per vessel, and have varied widely Specific identification in tissue sections of arterial cells expressing a recombinant protein has been reported by three groups, all working with genes other than luciferase.3,9,12,13 Histological identification was accomplished by histochemical staining for ,-galactosidase expression3 9or by immunohistochemistry for the HLA-B7 or Simian virus-40 (SV40) T antigen.12,13 None of these groups has presented quantitative data that document the existence of high-efficiency in vivo gene transfer, and in none of these studies was recombinant protein expression specifically quantitated.
Recent reports of the use of recombinant adenoviral vectors led us to attempt to use these vectors for in vivo arterial gene transfer. These reports have provided evidence that adenoviral vectors are capable of high-efficiency gene transfer both in vivo and ex vivo,4-17resulting in significant, easily detectable levels of recombinant protein production. 15, 18 In addition to the potential for adenoviral vectors to effect efficient gene transfer and high levels of recombinant gene expression, many of these studies incorporated a nuclear-targeted ,B-galactosidase marker gene to allow specific histological identification of transduced cells, thereby demonstrating simultaneous achievement of high-efficiency significant gene expression and histological localization..1518
In the present study, we used an adenoviral vector containing a nuclear-targeted ,3-galactosidase gene to perform direct in vivo gene transfer into the ballooninjured rat carotid artery. The purpose of the study was to determine the following in this well-recognized model of arterial injury: (1) the efficiency of in vivo adenoviral vector-mediated gene transfer, (2) the level of recombinant protein production consequent to gene transfer, (3) the cellular targets of gene transfer, and (4) the duration of recombinant gene expression. The results demonstrate that adenoviral vector-mediated gene transfer into the injured rat carotid artery results in efficient gene transfer into the vascular media, with levels of in vivo recombinant protein production significantly higher than any previously reported in arterial gene transfer studies.
Materials and Methods

Construction of Recombinant Adenoviral Vectors
A recombinant adenoviral vector (AvlLacZ4, Fig 1) 
Production of High-Titer Adenoviral Vectors
Highly purified AvlLacZ4 and AvlCf2 viruses were produced, stored, and titered as previously described. 20 Briefly, lysates of 293 cells infected with the recombinant virus were centrifuged through cesium chloride gradients. Purified virus was dialyzed and then stored at -80°C until use. To expedite use of the viral preparations, titer of purified viral stocks was determined by a "quick titer" method based on evaluation of the virus preparations by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by Coomassie Calif) calibrated with a standard curve generated by using purified E. coli l3-galactosidase (specific activity, 300 U/mg; Boehringer Mannheim). One unit of ,B-galactosidase releases 1 ,umol of 2-nitrophenol from the substrate 2-nitrophenyl-P3-D-galactoside in 1 minute at 37°C, pH 7.8. The activity assay gave a linear response to levels of the fB-galactosidase standard ranging from 1.5 to 1500 gU, with the amount of light emission at 1.5 gU approximately two to five times background. All assays were done in duplicate on 2-to 13-fold dilutions of the cell lysate. Assay samples with light emission below that generated by the 1.5-,uU standard were read as "undetectable."
Additional ensure adequate injury, the inflated catheter was passed a total of three times. After balloon injury, a segment of common carotid artery approximately 1 cm in length was isolated by placement of vascular clamps on the proximal common carotid artery and the proximal internal carotid artery. A plastic catheter was introduced through the external carotid arteriotomy, and the isolated vessel segment was flushed with M-199 medium before introduction of either adenoviral vectors or control infusate.
Adenoviral vector stocks were thawed, diluted, and maintained on wet ice until use. All stocks were used within 2 hours of thawing. For each rat, a total of 50 ,L diluted adenoviral vector was instilled into the isolated common carotid segment by means of a catheter placed in the external carotid artery. During infusion of the vector-containing medium, the isolated carotid segment became distended and remained so for the duration of the instillation period. After 20 minutes of incubation, the vector-containing medium was withdrawn, the external carotid was ligated, and blood flow through the common and internal carotid arteries was reestablished. Rats were allowed to recover from anesthesia and were returned to their cages. At varying time intervals after gene transfer, rats were killed by CO2 asphyxiation, and the left carotid artery was removed for analysis.
In Vivo Liposome-Mediated Gene Transfer was instilled into an isolated segment of left common carotid artery for 20 minutes, as described above for adenoviral vector-mediated gene transfer.
Measurement of /-Galactosidase Activity and Antigen After In Vivo Gene Transfer
The adventitia of the excised carotid artery was carefully removed. The vessel was then minced in lysis buffer containing 0.2% Triton X-100 and 100 mmol/L potassium phosphate, pH Histological, Histochemical, and Immunohistochemical Analysis A separate series of experiments, including 10 rats, was performed to obtain samples for histological analysis. Six carotid arteries were exposed to the AvlLacZ4 vector at a concentration of 1010 pfu/mL, and four arteries were exposed to vehicle only. On day 3 after gene transfer, the rats were killed, and the arteries were harvested. Four of the arteries that were exposed to the AvlLacZ4 vector and two of the arteries that were exposed to vehicle alone were removed and divided longitudinally. One half of each vessel was processed for histochemical examination; the other half was used for extraction and measurement of ,B-galactosidase, as described above. For the additional (two experimental and two control) arteries, the entire vessel was processed for histology, without longitudinal division and with no tissue extraction performed. Before histological analysis, all vessel segments were fixed with 2% formaldehyde and 0.2% glutaraldehyde for 20 minutes, rinsed in phosphate-buffered saline, and placed in X-Gal staining solution for 2 hours at 37°C. After 2 hours, the vessel segments were rinsed in phosphate-buffered saline and returned to the formaldehyde/glutaraldehyde fixative. A relatively short period of staining (2 hours) was used since a longer duration of staining occasionally resulted in a nonspecific background staining (diffuse blue). Our use of a short period of staining could potentially result in underestimation of the number of transduced cells because of the lack of staining of cells expressing low amounts of ,3-galactosidase. The estimated transduction efficiency therefore may represent a lower limit of transduction efficiency using the adenoviral vector.
X-Gal-stained arteries (both half-and whole-vessel segments) were Stained sections were examined by light microscopy for the presence of deep blue nuclei indicative of ,3-galactosidase expression. The number of X-Galstained cells and the total number of cells in the vascular media were determined by counting nuclei on sections stained with either nuclear fast red (for X-Galpositive nuclei) or hematoxylin and eosin (for total nuclei). For the half-vessel segments, the counted numbers of X-Gal-stained and total cells were multiplied by two in order to determine the number of cells per section of whole vessel. In this manner, for each vessel both transduced and total medial cells were counted from a total of six to eight sections per vessel, and the percentage of medial cell transduction was calculated. In addition, for the vessels receiving the AvlLacZ4 vector, the number of transduced cells in one half of a vessel segment (as determined by X-Gal staining) could be compared with the levels of 3-galactosidase antigen and activity in the lysates obtained from the opposite half of the same vessel.
Sections of whole vessels that had been stained with X-Gal were also processed for immunohistochemical detection of smooth muscle cell actin. Staining was performed using an antibody to smooth muscle cell actin (Sigma Chemical Co, St Louis, Mo) at a dilution of 1:20 000. Bound antibody was detected with a secondary antibody conjugated to horseradish peroxidase.
Results
In Vitro Transduction and Expression of /-Galactosidase Figs 3 and 4) . The level of expression resulting from liposome-mediated gene transfer is therefore at least one to two orders of magnitude below that detected after adenoviral vector-mediated gene transfer.
Duration of f3-Galactosidase Expression In Vivo
Thirty-one rats were included in a time-course study: 21 received the AvlLacZ4 vector, and 10 received "vehicle only" control infusions. Carotid arteries were harvested at 3, 7, 14, 28, and 42 days after injury and adenoviral vector-mediated gene transfer (Fig 5A). ,B-Galactosidase activity in AvlLacZ4-transduced vessels at 3 days was 210±45 mU/mg protein, similar to that found in the initial in vivo studies (Fig 4) . The corresponding values at 7, 14, 28, and 42 days were 340+155, 3.9+3.7, 2.8+0.94, and 2.2+2.1 mU/mg protein. Therefore, the high level of initial transgene expression persisted for at least 7 days but declined dramatically by day 14 after gene transfer. 83-Galactosidase antigen levels in the AvlLacZ4-transduced vessels followed a similar pattern with initially high levels at 3 and 7 days (109±28 and 215±72 ng/mg protein), followed by a steep decrease such that in the day-14 and -28 samples antigen levels were only 2.6±4.1 and 1.3 ± 1.5 ng/mg protein, respectively (Fig 5B) . By day 42, ,p-galactosidase antigen was undetectable. For all control vessels, both 8-galactosidase antigen and activity were below the limit of detection.
Histological and Histochemical Analysis of Transduced Vessels
For purposes of histological and histochemical analysis, an additional 10 rat carotid arteries were injured, exposed to the AvlLacZ4 vector (n=6) or vehicle alone (n=4), excised 3 days later, and stained with X-Gal. Gross observation of the luminal surface of X-Galstained arterial segments that were exposed to the AvlLacZ4 vector showed distinct blue dots as well as confluent dark blue areas (Fig 6A) . Gross examination of the X-Gal-stained arterial segments that were exposed to the vehicle alone showed occasional diffuse light blue staining on the abluminal surface (not shown). However, these control vessels showed absolutely no dark blue or punctate staining on either the abluminal or the luminal surface (Fig 6B) . Days post transduction Microscopic examination of tissue sections obtained from vessel segments exposed to AvlLacZ4 and stained with X-Gal revealed focal dark blue nuclear staining, suggestive of expression of nuclear-targeted ,B-galactosidase (Fig 7A) . Blue-staining cells were limited to the media of the vessel wall (Fig 7C) and were identified as smooth muscle cells by immunohistochemistry (Fig 7D) . Sections of experimental arteries showed extensive injury in the media, as evidenced by the fairly widespread coagulation necrosis of smooth muscle cells and absence of nuclei (Fig 7F) . In some areas, focal loss of cells between elastic laminas was observed (Fig 7C) . In addition, many sections revealed the presence of intra- mural hemorrhage within the vascular media (Fig 7E) . Substantial medial injury including hemorrhage and necrosis was also present in control vessels that were balloon-injured but into which only vehicle had been infused. Microscopic examination of sections of the control vessels revealed evidence of vascular injury but with total absence of deep blue staining in any of the layers of the vessel wall (Fig 7B) .
Estimation of Number of Transduced Cells per Vessel
The histological sections were used to obtain an estimate of the number of transduced cells per vessel and of the percentage of total medial cells that were transduced. The number of X-Gal-stained cells per histological section of whole vessel was 20±10 (mean±SEM; n=44 sections from six animals; range, 0 to 100 cells), and the number of total medial nuclei per histological section of whole vessel was 76+10 (mean--SEM; n=44 sections from six animals; range, 0 to 240 cells). The percentage of X-Gal-stained cells in the media of vessels taken from the six animals was 29±5% (mean-'-SEM; range, 15% to 43%). Counting of transduced and total cells was repeated by a second observer, with findings differing by less than 10% from those cited (data not shown). Assuming an SMC diameter of 20 gm, there are 500 layers of SMCs in a 10-mm length of carotid artery. With a mean of 20 transduced cells per layer, we calculated a total of 10 000 transduced cells per 10 mm of vessel.
As an additional means of determining the number of transduced cells per vessel segment, /3-galactosidase antigen and activity were measured in tissue extracts from the other half of four of the six vessel segments that were exposed to the AvlLacZ4 vector. Measured As a direct means of comparing lipofection and adenoviral vector-mediated gene transfer, we attempted liposome-mediated transfer of a plasmid expressing the same transcriptional unit present in the AvlLacZ4 vector. As expected from the historical comparisons made above, the level of gene transfer resulting from lipofection of the plasmid was far below that obtained with the AvlLacZ4 adenoviral vector. Although we did not make any attempts to further optimize the conditions for liposomemediated gene transfer into the injured rat carotid, the concentrations of plasmid DNA and Lipofectin reagent used in the present study (20 , (Figs 3 through  6) . In vessels infused with equal numbers of virions, the expression level of ,B-galactosidase varied over more than one order of magnitude. The number of transduced cells per histological section also varied widely (see "Results"). One likely cause for the observed range of gene transfer efficiencies is variability in the degree of vessel wall necrosis secondary to balloon injury. When cell necrosis is extensive (Fig 7F) , little or no transduction can occur; when cell viability is preserved, significant levels of gene transfer are possible (Fig 7A) . Efforts to improve the uniformity of arterial injury may prove helpful in decreasing experimental variability.
An additional potential difficulty in the present model is the possibility that some of the observed cytopathic effects may result from exposure of cells to high-titer adenoviral vectors. Akli et a128 reported significant cytopathogenicity after injection of a high-titer (3 x 101 pfu/mL) adenoviral vector suspension into rat brains. These authors found no evidence of cytopathogenicity after injections of suspensions of lower titer. In smooth muscle cells, since transduction of sheep arterial the present study, we reviewed histological sections taken from a small number of balloon-injured carotids both with and without exposure to high-titer adenoviral vectors (1010 pfu/mL). There appeared to be additional cell loss attributable to virion exposure (data not shown). A more extensive and systematic study of cytopathogenicity in blood vessels exposed to adenoviral vectors should be informative.
We documented high levels of gene expression for up to 7 days after gene transfer. Previous in vivo studies using adenoviral vectors have demonstrated long-term expression (over 1 year) in certain systems29 but not in others.30,31 Despite the limited duration of expression of the f3-galactosidase adenoviral vector in the injured rat carotid, we anticipate that this system will be useful for both pathophysiological and therapeutic studies. Informative in vivo gene expression studies can be carried out within several days after gene transfer,32 and therapy effective in preventing arterial proliferation has been successful when delivered as a single bolus dose immediately after the injury.33
In summary, direct in vivo gene transfer into the vascular media of injured arteries can be achieved at high efficiency using adenoviral vector-mediated gene transfer. The level of transgene expression is easily detectable and is as high or higher than expression of certain endogenous arterial proteins. In vivo adenoviral vector-mediated gene transfer has the potential to be a useful technique for the study of vascular pathophysiology and for vascular gene therapy.
